The Helmholtz Centre for Infection Research (HZI) is organised in the form of a GmbH (equals “Ltd.”). Shareholders are the Federal Republic of Germany (90 percent) and the federal states Lower-Saxony (nine percent) and Saarland (one percent).
Representatives from the shareholders are members of the supervisory board – together with experts from universities, clinics, economy, other research institutes and from the HZI itself. The highest governing body of the HZI meets twice a year, it takes the major policy decisions and appoints the two directors. The scientific committee advices the supervisory board. The middle management of the centre is composed of the heads of academic departments, administrative units and staff units.
Michael Manns graduated in medicine from the University of Mainz and the University of Vienna before completing his postgraduate training as internist and gastroenterologist at the Free University of Berlin, Germany, and the Johannes Gutenberg University of Mainz. After his time as a professor and staff physician at the 1st Department of Medicine of the University of Mainz and research associate at the Scripps Clinic and Research Foundation in La Jolla, USA, he joined in 1991 the Department of Gastroenterology, Hepatology and Endocrinology at Hanover Medical School (MHH) as director.
Since 2015 he is also Clinical Director of the HZI and Director of the Centre for Individualised Infection Medicine (CIIM).
Michael Manns has a long-term research interest in liver diseases with a main focus on viral hepatitis, autoimmune liver diseases, hepatocellular carcinoma, infectious diseases, liver transplantation and regenerative medicine.
He is Founder and Chairman of “Hep-Net”, a national network of competence on viral hepatitis, Chairman of the German Liver Foundation, Speaker of the Collaborative Research Center (Sonderforschungsbereich, SFB) 738 “Optimization of conventional and innovative transplants”, President of United European Gastroenterology (UEG) as well as honorary member of several scientific societies and member of various scientific academies among others of the Deutsche Akademie der Naturforscher Leopoldina (National Academy of Science) since 2002. Since 2015 he is member of the Scientific Panel for Health (SPH) of the European Commission in Brussels.